Tech Company Financing Transactions

Hyperion Therapeutics Funding Round

Hyperion Therapeutics closed a $40 million Series B funding round on 9/5/2007. Investors included Sofinnova Ventures, Highland Capital Partners and New Enterprise Associates.

Transaction Overview

Company Name
Hyperion Therapeutics
Announced On
9/5/2007
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors

Sofinnova Ventures (Lead Investor) (James Healy)

Highland Capital Partners (Bijan Salehizadeh)

New Enterprise Associates (Michael Raab)

WRF Capital

Proceeds Purpose
Chris Rivera, President and CEO of Hyperion said, "The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation (see press release dated August 28, 2007), build out our management team, advance our clinical trials in UCD and HE, and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD, AMMONUL® (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL® (sodium phenylbutyrate)."

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
601 Gateway Blvd 200
South San Francisco, CA 94080
USA
Phone
(650) 745-7802
Website
www.hyperiontx.com
Email Address
[email protected]
Overview
Hyperion Therapeutics, Inc. is a specialty biopharmaceutical company dedicated to improving patients' lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company's initial efforts are focused in the areas of gastroenterology and hepatology.
Profile
Hyperion Therapeutics LinkedIn Company Profile
Social Media
Hyperion Therapeutics Company Twitter Account
Company News
Hyperion Therapeutics News
Facebook
Hyperion Therapeutics on Facebook
YouTube
Hyperion Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Don Santel
  Don Santel LinkedIn Profile  Don Santel Twitter Account  Don Santel News  Don Santel on Facebook
Chief Financial Officer
Jeffrey Farrow
  Jeffrey Farrow LinkedIn Profile  Jeffrey Farrow Twitter Account  Jeffrey Farrow News  Jeffrey Farrow on Facebook
Chief Medical Officer
Bruce Scharschmidt
  Bruce Scharschmidt LinkedIn Profile  Bruce Scharschmidt Twitter Account  Bruce Scharschmidt News  Bruce Scharschmidt on Facebook
Vice President
Christine Nash
  Christine Nash LinkedIn Profile  Christine Nash Twitter Account  Christine Nash News  Christine Nash on Facebook
VP - Bus. Development
Natalie Holles
  Natalie Holles LinkedIn Profile  Natalie Holles Twitter Account  Natalie Holles News  Natalie Holles on Facebook
VP - Regulatory Affairs
Ashley Gould
  Ashley Gould LinkedIn Profile  Ashley Gould Twitter Account  Ashley Gould News  Ashley Gould on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/5/2007: Atempo venture capital transaction
Next: 9/6/2007: 3Tier venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.